GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects

Annals of Surgery

Volumn 257, Issue 5, 2013, Pages 894-899

  Jiménez, Amanda ^a   Casamitjana, Roser ^a,b,c   Flores, Lílliam ^a,b,c   Delgado, Salvadora ^a   Lacy, Antonio ^a,c   Vidal, Josep ^a,b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

gastric bypass; GLP 1; glucagon; insulin secretion; type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BARIATRIC SURGERY; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; RELAPSE; REMISSION; ROUX EN Y GASTRIC BYPASS; STOMACH BYPASS; TEST MEAL; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY COMPOSITION; C-PEPTIDE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GASTRIC BYPASS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY, MORBID; TREATMENT OUTCOME;

EID: 84876273519     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31826b8603     Document Type: Article

References (34)

1. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467-484.
2. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248-256.
3. Scott WR, Batterham RL. Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy:understanding weight loss and improvementsintype2diabetesaf-ter bariatric surgery. Am J Physiol Regul Integr Comp Physiol. 2011;301:R15-R27.
4. Rubino F, R'bibo SL, del Genio F, et al. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat Rev Endocrinol. 2010;6: 102-109.
5. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339-350.
6. Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg. 2010;252:966-971.
7. Bose M, Teixeira J, Olivan B, et al. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010;2:47-55.
8. Falkén Y, Hellström PM, Holst JJ, et al. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96:2227-2235.
9. Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479-2485.
10. Kashyap SR, Daud S, Kelly KR, et al. Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond). 2010;34: 462-471.
11. Vidal J, Nicolau J, Romero F, et al. Long-term effects of Roux-en-Y gastric bypass surgery on plasma glucagon-like peptide-1 and islet function in morbidly obese subjects. J Clin Endocrinol Metab. 2009;94:884-891.
12. Goldfine AB, Mun EC, Devine E, et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab. 2007;92:4678-4685.
13. Plum L, Ahmed L, Febres G, et al. Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss. Obesity (Silver Spring). 2011;19:2149-2157.
14. Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2010;6:254-259.
15. Di Giorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid-to long-term follow-up. Surg Obes Relat Dis. 2010;6:249-253.
16. Kim S, William O. Long-term follow-up of the metabolic profiles in obese patients with type 2 diabetes mellitus after Roux-en-Y gastric bypass. Ann Surg. 2010;251:1049-1055.
17. Morínigo R, Vidal J, Lacy AM, et al. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects. Ann Surg 2008;247:270-275.
18. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840-846.
19. Radaelli T, Farrell KA, Huston-Presley L, et al. Estimates of insulin sensitivity using glucose and C-Peptide from the hyperglycemia and adverse pregnancy outcome glucose tolerance test. Diabetes Care. 2010;33:490-494.
20. Maki KC, Rains TM, Dicklin MR, et al. Repeatability of indices of insulin sensitivity and secretion from standard liquid meal tests in subjects with type 2 diabetes mellitus or normal or impaired fasting glucose. Diabetes Technol Ther. 2010;12:895-900.
21. Boston RC, Stefanovski D, Moate PJ, et al. MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther. 2003;5:1003-1015.
22. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94:3171-3182.
23. Isbell JM, Tamboli RA, Hansen EN, et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care. 2010:33:1438-1442.
24. Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes. 2011;60:2308-2314.
25. Dirksen C, Hansen DL, Madsbad S, et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care. 2010;33:375-377.
26. Shah P, Vella A, Basu A, et al. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000;85:4053-4059.
27. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439.
28. Després JP. Intra-abdominal obesity: an untreated risk factor for type 2 diabetes and cardiovascular disease. J Endocrinol Invest. 2006;29:77-82.
29. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Increased circulating and visceral adipose tissue expression levels of YKL-40 in obesity-associated type 2 diabetes are related to inflammation: impact of conventional weight loss and gastric bypass. J Clin Endocrinol Metab. 2011;96:200-209.
30. Vázquez LA, Pazos F, Berrazueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90:316-322.
31. Nannipieri M, Mari A, Anselmino M, et al. The role of beta cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab. 2011;96:E1372-E1379.
32. Nolan CJ, Prentki M. The islet beta-cell: fuel responsive and vulnerable. Trends Endocrinol Metab. 2008;19:285-291.
33. Owens DR, Luzio SD, Coates PA. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diabet Med. 1996;13:S19-S24.
34. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type2 diabetes (LEAD-3 Mono): arandomised, 52-week, phase III, doubleblind, parallel-treatment trial. Lancet. 2009;373:473-481.